By Chaitanya
BBA Finance Graduate & 6+ Years of Experience in Stock market & Finance
Sudarshan Pharma Industries Ltd witnessed a notable surge in its share price on Monday, August 18, 2025, climbing by 4.64% to Rs 32.50. This positive momentum comes on the back of the company’s impressive turnaround net profit in the first quarter of the financial year 2025 (Q1 FY25) and a strategic acquisition of significant pharma manufacturing assets. The company, a key player in the pharmaceutical sector, has successfully shifted from a net loss position to profitability, signalling a robust Sudarshan Pharma turnaround and a promising outlook.
Q1 FY25 Performance: A Return to Profitability
For the quarter ending June 30, 2025, Sudarshan Pharma Industries Ltd reported a net profit of approximately Rs 3.959 crore (Rs 39.59 million). This marks a substantial improvement from the net loss of Rs 1.207 crore (Rs 12.07 million) recorded in the same quarter last year. This remarkable turnaround was accompanied by a significant increase in net sales, which rose to Rs 145.26 crore in Q1 FY25, up from Rs 99.2 crore year-on-year. The company’s basic and diluted Earnings Per Share (EPS) also saw a positive shift, moving to Rs 0.16 from a loss per share of Rs -0.05 in the previous year. These figures, reported by the company on August 15, 2025, highlight effective operational management and growing market demand.
Quarterly Financial Snapshot
To provide a clearer picture of the company’s recent performance trajectory, here is a summary of the latest quarterly financials in Crores (INR), as detailed in company reports:
| Quarter | Revenue | Expenses | Operating Profit | Operating Profit Margin % | EBITDA | Interest | Depreciation | PBT (Profit Before Tax) | Tax % | Net Profit | EPS (₹) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 2024 | 100 | 97 | 2 | 2% | 3 | 4 | 1 | -2 | 22% | -1 | 0.27 |
| Sep 2024 | 129 | 115 | 13 | 10% | 14 | 4 | 0 | 10 | 26% | 7 | 3 |
| Dec 2024 | 116 | 108 | 7 | 6% | 8 | 4 | 0 | 4 | 29% | 3 | 0 |
| Mar 2025 | 162 | 147 | 14 | 9% | 15 | 4 | 1 | 10 | 25% | 7 | 0 |
| Jun 2025 | 147 | 134 | 11 | 8% | 12 | 6 | 1 | 5 | 27% | 4 | 0 |
Strategic Asset Acquisition to Boost Manufacturing
Adding to the positive sentiment, Sudarshan Pharma announced a significant strategic move: the acquisition of pharma manufacturing assets worth Rs 25.50 crore from Srigen Lifesciences Pvt Ltd. This acquisition includes essential assets such as land, buildings, plant & machinery, covering an area of approximately 1563.15 square metres. This move is expected to significantly enhance Sudarshan Pharma’s manufacturing capabilities and production capacity, positioning the company for greater operational efficiency and market reach. Market news outlets highlighted this acquisition as a key growth driver, alongside the strong quarterly results.
Stock Performance and Market Overview
The company’s market capitalization currently stands at a robust Rs 770.11 crore. While the stock’s 52-week high is Rs 53.50 and its 52-week low is Rs 15.51, reflecting market volatility, Sudarshan Pharma has delivered impressive returns to its investors over the longer term. The stock has generated a multibagger return of 307% over the past two years and a solid 71% return in the last one year. However, it’s worth noting that the stock has seen a 28% correction in 2025 so far, presenting potential entry points for investors keen on long-term growth.
Annual Financial Highlights for FY25
Looking at the broader picture, Sudarshan Pharma’s annual performance for the fiscal year 2025 also paints a promising outlook. The total revenue for FY25 reached ₹507.57 crore, marking an 8.89% increase from the previous year. Total expenses stood at ₹483.12 crore, contributing to an EBIT (Earnings Before Interest and Taxes) margin of approximately 7.76%. The company achieved a net profit margin of around 2.75%, with a basic EPS of ₹0.16 for the full year. Interest expenses accounted for 3.12% of operating revenues, while employee costs were a modest 0.97% of operating revenues, showcasing efficient cost management.
Conclusion
Sudarshan Pharma Industries Ltd’s recent Q1 FY25 results, coupled with its strategic acquisition, underscore a significant positive shift in its financial health and operational capabilities. The successful Sudarshan Pharma turnaround is a testament to the company’s resilient business model and its proactive steps towards expansion. With strengthened manufacturing capacities and a return to profitability, Sudarshan Pharma appears well-positioned for sustained growth in the dynamic pharmaceutical market, offering an optimistic outlook for its stakeholders.
Disclaimer: All stock-related information, financial results, Price Targets and ratings shared on IPOC are strictly for informational and educational purposes only. The views and investment tips expressed by investment experts/broking houses/rating agencies on IPOcenter.in are their own, and not that of the website or its management None of the content published here should be considered as financial advice or a recommendation to invest. IPOC and its authors are not liable for any losses arising from decisions made based on the content of this article. Please consult a SEBI-registered financial advisor before making any investment decisions. The images used in this article are generated Images and meant for illustration purposes only.
